31
Jan
2012
Posted in I - Series E, Q - 4Q11, R - WEST, X - Cardiology, X - Device (Diagnostic), X - Metabolism, XX - CA
Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.
31
Jan
2012
Posted in I - Series E, Q - 4Q11, R - WEST, X - Autoimmune, X - Cardiology, X - Inflammation, XX - CA
Portola Pharmaceuticals (South San Francisco, CA) a clinical-stage small moelcule company focused on acute and chronic cardiovascular and autoimmune and inflammatory diseases, closed an $89M Series E financing. Participants included Temasek, Eastern Capital Limited, D.E. Shaw, Adage Capital Management, BBT Capital Management, Janus Capital Group and Pac-Link BioVentures.
31
Jan
2012
19
Jan
2012
Posted in I - Series B, Q - 3Q11, R - WEST, X - Cardiology, X - Renal, XX - CA
Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on development of adaptable non-absorbed polymeric drugs to for congestive heart failure, chronic kidney disease, end stage renal disease and hypertension, closed a $36M Series B financing. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
Thanx for your patience as we [...]
01
Sep
2011
Posted in I - Series B, Q - 2Q11, R - INTERNATIONAL, X - Cardiology
Milestone Pharmaceuticals (Canada) a development-stage pharmaceutical company focused on small molecules for atrial arrhythmias and angina, closed a $13M Series B financing. Participants include Pappas Ventures, GO Capital, Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation.
The 2Q11 OnBioVC Trend Analysis will be published on Tue 6 September. Advertising opportunities are still available. Reach [...]
09
Aug
2011
Posted in I - Series B, Q - 2Q11, R - WEST, X - Cardiology, X - Renal, XX - CA
Sorbent Therapeutics (Sunnyvale, CA) a clinical-stage biopharmaceutical company focused on cardiovascular and renal disorders, closed a $36M Series B financing, bringing the total round to $53M. Participants include Novartis Venture Funds, Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem.
13
Apr
2011
Posted in I - Series C, Q - 1Q11, R - WEST, X - CNS, X - Cardiology, XX - CA
NextWave Pharmaceuticals (Cupertino, CA) a clinical-stage specialty pharmaceutical focused on cardiovascular and CNS diseases, closed a $45M Series C financing. Participants include Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures.
23
Mar
2011
18
Jan
2011
10
Jan
2011
04
Jan
2011
23
Nov
2010
18
Oct
2010